Business Context and Reporting Period
This Form 8-K Current Report was filed by Shuttle Pharmaceuticals Holdings, Inc. on April 23, 2024. The filing reports an "Other Event" (Item 8.01) regarding an upcoming investor presentation by the Company's Chief Executive Officer, Dr. Anatoly Dritschilo.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on the announcement of a corporate event.
Outlook, Management Commentary, and Risks
- Upcoming Presentation: Dr. Dritschilo will present at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024, in Las Vegas.
- Key Topics:
- Progress toward clinical and scientific milestones for the Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment.
- Plans for the subsidiary, Shuttle Diagnostics, Inc., including the development of predictive biomarkers for prostate cancer outcomes following radiation therapy.
- Development of a novel PSMA ligand for theranostic applications.
- Access: The presentation will be webcast and available for replay on the Company's website.
- Forward-Looking Statements: The filing includes standard disclaimers that statements regarding future results, strategy, and plans are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the date and time of the Planet MicroCap Showcase presentation (May 1, 2024).
- Confirm the specific clinical trial status of Ropidoxuridine for glioblastoma via the upcoming webcast or subsequent filings.
- Review the development timeline for Shuttle Diagnostics' prostate cancer biomarkers and PSMA ligand.
- Check the Company's website (shuttlepharma.com) for the webcast replay and the attached press release (Exhibit 99.1).